http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HR-P20080255-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9264830abb1546ae267a47cad928c5bd
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4741
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-724
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-724
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4741
filingDate 2008-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92c57ea4ea680252f530f37e30104243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55e3108d6652001e24a3335fcb348389
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e0205f0ff25ec2df068d49b2280d26b
publicationDate 2008-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber HR-P20080255-A2
titleOfInvention USE OF CYCLETHANINE AND OTHER FUROPYRIDINS FOR THE TREATMENT OF PRINCIPLE SYSTOLIC HYPERTENSION, ISOLATED SYSTOLIC HYPERTENSION, INCREASED PULSE PRESSURE AND GENERAL HYPERTENSION
abstract The present invention provides mixtures of cycletanin and other furopyridines for the treatment of pulse hypertension, isolated systolic hypertension and general hypertension, in monotherapeutic forms (furopyridine only) and in mixtures combined with other antihypertensive agents, cardiovascular antidiabetic agents and / or oral agents. Such mixtures of furopyridine comprise enantiomerically pure (positive or negative) embodiments and non-racemic enantiomeric mixtures, and comprise daily doses of less than 50 mg. Further methods are provided for the treatment of general or systolic hypertension, wherein mixtures of furopyridine alone or in combination with another agent for the treatment of general hypertension or systolic hypertension, and related complications, are administered to patients.
priorityDate 2005-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414372168
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54910
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12210217
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554760

Total number of triples: 22.